Fundraising Fox
/Companies
Sign in

GigaGen

South San Francisco, US · Delaware corporation

Find your way into GigaGen

Each arrow is one introduction. Sign up to fill in the first one.

1,113 people can intro you to David

Ask William Krut to introduce you to David Johnson

You →William · together at GigaMune →David

Sign up to find every way you can get introduced to GigaGen

  • Your email: who you already know at GigaGen, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the GigaGen team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

GigaGen, a subsidiary of Grifols, develops recombinant polyclonal and monoclonal antibody therapies for immunodeficiencies, infectious diseases, transplant rejection, and cancer using single-cell discovery technologies. The company runs a pipeline of drug candidates including a lead CTLA-4 oncology asset and recombinant hyperimmunes for hepatitis B, rabies, and botulinum toxin.

BiotechDeep Tech

Founders & leadership

DJDavid Johnson
David JohnsonFounder and CEO2010–2021David Johnson is CEO of Waymark Clinical, which operates clinical trials using an AI platform; he previously founded GigaGen, developing recombinant antibody therapies that were sold to Grifols in 2021, and was among Natera's founding members and COO. Johnson holds a BS in Biology from Duke University, a PhD in Genetics from Stanford University, and an MBA from the Haas School of Business at UC Berkeley.
CW
Chuck WilsonNamed on SEC filing
CKCarter Keller
Carter KellerNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$36.1M disclosed across 1 round · 2017

▶$36.1MraisedJul 2017 · 8 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Chuck WilsonDirector
  • Carter KellerDirector
  • David JohnsonExecutive Officer, Director
Offering amount
$36.1M
Amount sold
$36.1M
Proceeds to insiders
$3M
First sale
Jul 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

AmgenAmgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis. Its Danish operation, Amgen Danmark, focuses on improving health outcomes for patients and their families in Denmark.
Biogen IdecBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
ExagenExagen develops diagnostic and monitoring tests for autoimmune diseases, including tools to distinguish connective tissue disease and assess lupus prognosis and progression. The company serves healthcare professionals and patients with chronic autoimmune conditions.

Companies working in the same space as GigaGen.

Non-dilutive funding · 17 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2017$3M
National Institutes of Health (NIH)National Institutes of HealthPhase II2016$1.6M
National Institutes of Health (NIH)National Institutes of HealthPhase II2016$1.5M
National Institutes of Health (NIH)National Institutes of HealthPhase I2015$265K
National Institutes of Health (NIH)National Institutes of HealthPhase I2015$225K
National Institutes of Health (NIH)National Institutes of HealthPhase I2015$224.8K
National Institutes of Health (NIH)National Institutes of HealthPhase II2014$912.7K
National Institutes of Health (NIH)National Institutes of HealthPhase I2014$249.1K
National Institutes of Health (NIH)National Institutes of HealthPhase I2014$217.5K
National Institutes of Health (NIH)National Institutes of HealthPhase II2013$1.1M
National Science FoundationPhase II2012$500K
National Institutes of Health (NIH)National Institutes of HealthPhase I2012$205.7K
National Institutes of Health (NIH)National Institutes of HealthPhase I2012$189.6K
National Institutes of Health (NIH)National Institutes of HealthPhase I2012$156.4K
Department of EnergyPhase I2012$150K
National Institutes of Health (NIH)National Institutes of HealthPhase I2011$201.6K
National Science FoundationPhase I2011$150K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

GigaGen Closes $50M Deal With Grifolsgigagen.com · Jul 2017

Frequently asked questions

What does GigaGen do?
GigaGen, a subsidiary of Grifols, develops recombinant polyclonal and monoclonal antibody therapies for immunodeficiencies, infectious diseases, transplant rejection, and cancer using single-cell discovery technologies. The company runs a pipeline of drug candidates including a lead CTLA-4 oncology asset and recombinant hyperimmunes for hepatitis B, rabies, and botulinum toxin.
Who founded GigaGen?
GigaGen was founded by David Johnson.
How much funding has GigaGen raised?
GigaGen has disclosed $36.1M raised across 1 round.
Where is GigaGen headquartered?
GigaGen is headquartered in South San Francisco, US.